Clinical Trials Browser

Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Genital Neoplasms, Female, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Radiation Injuries, Rectal Neoplasms

Clinical Trials

RADVAN

Prospective Clinical Study Comparing PROMS After Adaptive or Conventional Radiotherapy in Prostate Cancer

PRIMORDIUM

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

MOMENTUM

Proton-Based Stereotactic Ablative Body Radiotherapy for Prostate Cancer

Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT

REVELUTION

X-SMILE

Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization

Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

Pembro With Radiation With or Without Olaparib

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

SENTRY

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer

STEEL

DIVINE

INTREPId (INTermediate Risk Erection PreservatIon Trial)

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer

MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

SPRINTR-REAL

DECREASE

PRORAD

OLIGOPELVIS2

FAST-ONE

JUMP

SIB

GrandP/SPCG19

Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPC

Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer

Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer

IP4-CHRONOS

Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer

HypoElect

PCS-XII

IP2-ATLANTA

PCS IV

PRIS

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer

PEACE1

PEGASUS

Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer